ArticleFrontiers in psychiatry2026
Acupuncture for irritable bowel syndrome comorbid with anxiety and depression: study protocol for a placebo run-in, randomized clinical trial.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastrointestinal and psychological symptoms jointly motivate patients with irritable bowel syndrome (IBS) to seek medical care, with the latter often exacerbating the difficulty of achieving overall improvement. Although acupuncture has been shown to improve gastrointestinal symptoms in the general IBS population, the evidence in individuals with psychological disturbances remains insufficient. Methods: This will be a placebo run-in, randomized controlled trial. After the 1-week sham acupuncture intervention run-in period, the 80 eligible IBS patients without strong placebo responses will be randomly assigned to the true acupuncture (TA) group and sham acupuncture (SA) group. During the 4-week intervention period, all patients will receive the assigned intervention three times per week, followed by an 8-week follow-up. The primary endpoint is the response rate, defined as the proportion of patients with a decrease of greater than or equal to 50 points in the IBS Symptom Severity Scale (IBS-SSS) score from baseline at week 4. Secondary outcomes include the response rates at other time points, original IBS-SSS scores, Hospital Anxiety and Depression Scale (HADS), Visual Analog Scale (VAS) for abdominal pain, satisfaction with bowel habits, blinding assessment, and Credibility/Expectancy Questionnaire. Safety will be monitored and recorded during the trial. Discussion: This trial will provide individualized evidence for addressing IBS with key comorbidities while excluding placebo response. The results of this trial will be published in a peer-reviewed journal. Clinical Trial Registration: https://itmctr.ccebtcm.org.cn/mgt/project/view/1985616257155727360, identifier ITMCTR2025002100.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.